LOGIN  |  REGISTER
Recursion

List of Biotech and Pharma Companies Using Artificial Intelligence

Company
Last Trade
Change
Volume
Shares Out
Market Cap
US$ 725.79
-12.42 -1.68
4.30M
899.32M
US$ 652.720B
US$ 36.05
-1.60 -4.25
350,393
5.52B
US$ 199.000B
US$ 349.29
3.49 1.01
2.76M
381.22M
US$ 133.160B
US$ 83.89
1.01 1.22
6.33M
1.28B
US$ 107.380B
US$ 215.11
1.43 0.67
801,190
162.35M
US$ 34.920B
US$ 154.92
0.19 0.12
2.10M
181.50M
US$ 28.120B
US$ 60.96
0.45 0.74
5.40M
456.87M
US$ 27.850B
US$ 61.64
1.81 3.03
4.85M
390.60M
US$ 24.080B
US$ 106.99
-0.36 -0.34
936,149
199.07M
US$ 21.300B
US$ 86.84
-1.22 -1.39
656,624
239.74M
US$ 20.820B
US$ 166.02
1.84 1.12
1.28M
111.62M
US$ 18.530B
US$ 62.06
1.20 1.97
2.46M
225.72M
US$ 14.010B
US$ 151.08
-2.64 -1.72
633,291
82.56M
US$ 12.470B
US$ 96.75
1.91 2.01
935,181
121.70M
US$ 11.770B
US$ 60.59
0.01 0.02
1.17M
192.65M
US$ 11.670B
US$ 72.86
-1.30 -1.75
3.14M
158.60M
US$ 11.560B
US$ 25.80
-0.51 -1.94
1.23M
435.99M
US$ 11.250B
US$ 25.76
0.65 2.59
9.32M
384.82M
US$ 9.910B
US$ 40.73
2.47 6.46
1.95M
222.26M
US$ 9.050B
US$ 52.85
1.13 2.18
2.12M
158.89M
US$ 8.400B
US$ 80.60
1.80 2.28
916,560
86.66M
US$ 6.980B
US$ 135.05
-1.85 -1.35
1.10M
51.14M
US$ 6.910B
US$ 43.54
0.96 2.25
10.48M
152.40M
US$ 6.640B
US$ 35.64
0.71 2.03
811,996
172.09M
US$ 6.130B
US$ 48.86
0.15 0.31
665,104
74.03M
US$ 3.620B
US$ 17.26
1.62 10.36
915,270
186.89M
US$ 3.230B
US$ 87.41
7.39 9.24
529,366
27.47M
US$ 2.400B
US$ 46.64
-0.38 -0.81
290,193
38.23M
US$ 1.780B
US$ 9.28
-0.27 -2.83
1.37M
160.99M
US$ 1.490B
US$ 3.23
-0.11 -3.15
8.08M
412.08M
US$ 1.330B
US$ 14.84
0.13 0.88
982,887
86.43M
US$ 1.280B
US$ 7.23
-0.07 -0.96
6.38M
172.17M
US$ 1.240B
US$ 9.65
-0.34 -3.40
1.09M
115.03M
US$ 1.110B
C$ 4.21
0.11 2.68
880,419
248.96M
C$ 1.050B
US$ 7.43
-0.04 -0.54
1.97M
107.00M
US$ 795.010M
US$ 8.09
-0.04 -0.49
651,721
91.04M
US$ 736.510M
US$ 7.85
-0.31 -3.80
718,239
77.11M
US$ 605.310M
US$ 6.16
-0.30 -4.64
1.33M
89.70M
US$ 552.100M
US$ 5.73
0.05 0.88
602,430
78.15M
US$ 447.800M
US$ 2.65
0.02 0.57
1.32M
168.92M
US$ 446.790M
US$ 3.02
-0.01 -0.33
69,008
139.82M
US$ 422.260M
US$ 2.12
0.08 3.68
2.53M
186.64M
US$ 394.740M
US$ 2.42
-0.04 -1.43
1.86M
138.95M
US$ 335.560M
US$ 6.44
0.87 15.62
1.34M
45.20M
US$ 291.090M
US$ 12.22
-0.18 -1.45
57,430
23.48M
US$ 286.930M
US$ 2.27
-0.50 -18.05
2.40M
114.86M
US$ 260.730M
US$ 4.23
-0.17 -3.86
1.85M
58.52M
US$ 247.540M
US$ 3.93
-0.08 -2.00
330,497
60.85M
US$ 239.140M
C$ 1.37
0.03 2.24
254,776
165.88M
C$ 227.260M
US$ 9.54
8.79 1.00
46,261
23.12M
US$ 220.450M
US$ 5.84
0.00 0.00
0
37.47M
US$ 218.820M
US$ 2.82
0.06 2.17
72,092
66.44M
US$ 187.360M
US$ 7.73
-0.02 -0.26
269,774
18.42M
US$ 142.390M
US$ 5.10
1.11 27.82
400
27.08M
US$ 138.110M
US$ 2.35
0.00 0.00
0
49.43M
US$ 116.160M
C$ 1.45
-0.10 -6.45
79,667
74.08M
C$ 107.420M
US$ 0.65
0.0003 0.05
392,715
153.83M
US$ 99.370M
C$ 0.10
0.00 0.00
0
100.02M
C$ 10.000M
US$ 2.51
-0.02 -0.83
57,075
32.20M
US$ 80.790M
US$ 0.64
0.03 5.64
791,419
125.80M
US$ 79.880M
US$ 0.44
0.05 12.33
480,141
158.72M
US$ 70.000M
US$ 1.93
0.009 0.47
9,740
31.02M
US$ 59.840M
US$ 1.51
-0.10 -6.21
130,979
37.10M
US$ 56.020M
US$ 1.42
0.005 0.35
415,929
37.42M
US$ 52.950M
US$ 1.71
0.02 1.18
84,665
26.67M
US$ 45.610M
US$ 1.71
-0.04 -2.29
288,418
26.35M
US$ 45.060M
US$ 0.72
0.06 8.92
276,682
57.89M
US$ 41.620M
US$ 1.48
-0.04 -2.63
201,107
27.60M
US$ 40.850M
C$ 0.44
-0.02 -3.33
10,250
93.38M
C$ 40.620M
US$ 1.65
0.07 4.43
29,384
22.41M
US$ 36.980M
US$ 2.87
-0.12 -3.98
54,046
10.78M
US$ 30.950M
C$ 0.27
-0.02 -7.02
125,750
113.10M
C$ 29.970M
US$ 0.17
-0.006 -3.51
789,188
162.86M
US$ 26.870M
US$ 1.18
-0.04 -2.89
183,120
20.75M
US$ 24.380M
US$ 0.06
0.00 0.00
0
407.29M
US$ 24.030M
C$ 0.26
-0.005 -1.92
9,000
90.89M
C$ 23.180M
US$ 9.41
-0.26 -2.69
30,450
2.40M
US$ 22.580M
C$ 0.14
-0.01 -6.67
83,500
159.67M
C$ 22.350M
US$ 0.28
0.01 3.70
321,660
77.45M
US$ 21.690M
US$ 1.26
0.00 0.00
594,976
16.26M
US$ 20.490M
US$ 2.38
0.55 30.05
120,022
7.09M
US$ 16.870M
US$ 1.87
-0.12 -6.03
15,465
8.39M
US$ 15.690M
US$ 1.60
-1.63 -50.39
2.29M
9.39M
US$ 15.020M
C$ 0.10
-0.005 -4.76
187,777
140.64M
C$ 14.060M
US$ 0.48
-0.0036 -0.74
29,371
27.99M
US$ 13.460M
US$ 0.59
0.004 0.68
388,039
22.45M
US$ 13.340M
US$ 1.49
0.19 14.62
197,524
8.71M
US$ 12.980M
US$ 0.32
0.01 3.76
604,221
40.44M
US$ 12.820M
US$ 0.41
0.05 13.09
458,036
31.06M
US$ 12.640M
C$ 0.02
0.00 0.00
1.22M
451.63M
C$ 9.030M
US$ 0.34
-0.08 -18.19
5,241
24.39M
US$ 8.270M
C$ 0.09
-0.005 -5.26
130,566
90.29M
C$ 8.130M
US$ 1.21
-1.90 -61.09
9,039
6.63M
US$ 8.020M
US$ 1.16
-0.18 -13.43
389,632
6.67M
US$ 7.740M
US$ 0.33
-0.02 -6.68
183,672
23.26M
US$ 7.610M
US$ 2.69
-0.22 -7.41
94,820
2.71M
US$ 7.280M
US$ 0.49
-0.03 -6.10
112,080
14.09M
US$ 6.950M
US$ 3.07
0.09 3.02
88,339
2.22M
US$ 6.820M

Latest News From Biotech and Pharma Companies Using Artificial Intelligence


Conduit Pharmaceuticals Expands Partnership with Sarborg to Leverage Machine Learning Data Analysis for Pipeline Optimization

Conduit expands its partnership with Sarborg to apply advanced machine learning-driven analysis on clinical data from its AstraZeneca-acquired assets, aiming to uncover new insights and optimize development pathways. NAPLES, Fla. and CAMBRIDGE, United Kingdom, April 07, 2025 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Inc. (Nasdaq: CDT) ("Conduit Pharmaceuticals" or "Conduit" or the “Company”) today announces that it has entered into an additional license and use... Read more


NetraMark And Worldwide Clinical Trials Announce Agreement To Transform Clinical Trial Design With AI-Powered Precision

TORONTO, April 3, 2025 /PRNewswire/ - NetraMark Holdings Inc. (the "Company" or "NetraMark") (CSE: AIAI) (OTCQB: AINMF) (Frankfurt: PF0) a premier artificial intelligence (AI) company that is transforming clinical trials with AI powered precision analytics in the pharmaceutical industry, today announced a global agreement with Worldwide Clinical Trials ("Worldwide"), a full-service, global contract research organization (CRO). This strategic partnership introduces... Read more



HEALWELL AI Completes Acquisition of Orion Health, Becoming a Global Leader in Healthcare Data Interoperability and Artificial Intelligence

HEALWELL has acquired Auckland, New Zealand-based Orion Health Holdings Limited ("Orion Health"), a global healthcare intelligence platform providing subscription licenses and services to marquee public sector clients with data interoperability and healthcare navigation products. Orion Health1 has approximately 400 employees with offices in 11 countries globally. Its software solutions currently support over 70 public and private sector customers representing 150 million... Read more


Alpine ENT Expands Partnership with CareCloud, Implements FrontDesk Assist to Enhance Patient Experience

SOMERSET, N.J., March 26, 2025 (GLOBE NEWSWIRE) -- CareCloud, Inc. (the “Company”) (Nasdaq: CCLD, CCLDO), a leading provider of healthcare technology and AI-powered revenue cycle management (RCM) solutions, today announced the expanded adoption of its services by Alpine Ear, Nose & Throat PC, a premier otolaryngology group based in Colorado. Following a successful RCM engagement, Alpine ENT has now implemented CareCloud FrontDesk Assist—a comprehensive front-office... Read more


Charles River Laboratories and Valo Health Identify a Potential Therapeutic for Lupus Using Logica®, an AI-Powered Drug Discovery Platform

First Logica-identified candidate marks a progression-based milestone in ongoing partnership with Pioneering Medicines, Flagship Pioneering’s in-house drug development unit WILMINGTON, Mass. & CAMBRIDGE, Mass. / Mar 25, 2025 / Business Wire / Charles River Laboratories International, Inc. (NYSE: CRL) and Valo Health, Inc. today announced the identification of an advanceable product candidate for the treatment of different forms of lupus and other autoimmune indications... Read more


Anixa Biosciences Enters Letter of Intent with VERDI Solutions to Develop Artificial Intelligence-Guided Personalized and Off-the-Shelf Cancer Vaccines

VERDI's personalized vaccines have demonstrated safety and efficacy in cancer patients SAN JOSE, Calif., March 25, 2025 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that it has entered into a letter of intent with VERDI Solutions, GmbH to develop personalized and off-the-shelf peptide vaccines for cancer patients. VERDI Solutions, headquartered... Read more


Predictive Oncology Successfully Develops Predictive Models Derived from Never-Before-Seen Compounds for Prevalent Cancer Indications Including Breast, Colon and Ovary

Company successfully developed predictive models derived from 21 unique compounds from the Natural Products Discovery Core at the University of Michigan Tumor response models for novel compounds represent true drug discovery using Predictive's active machine learning platform PITTSBURGH, March 25, 2025 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI), a leader in AI-driven drug discovery, announced today that it has successfully developed predictive... Read more


Optimind Pharma Enters into Letter of Intent with Monjin to Acquire AI Business

Toronto, Ontario--(Newsfile Corp. - March 24, 2025) - Optimind Pharma Corp. (CSE: OMND) (the "Optimind" or the "Company") announces that it has entered into a non-binding letter of intent dated March 18, 2025, (the "LOI") to acquire all of the issued and outstanding shares (the "Transaction") of Monjin Interviews Private Limited ("Monjin"), a corporation formed under the laws of India. The Transaction is an arm's length transaction. About Monjin - https://www.monjin.c... Read more


Ventripoint Diagnostics Publishes Whitepaper on the Use of AI in Whole-Heart Analysis

Toronto, Ontario – TheNewswire - March 24, 2025 - Ventripoint Diagnostics Ltd. ("Ventripoint" or the "Company"), (TSXV:VPT; OTC:VPTDF) is pleased to announce the release of a whitepaper comparing the performance of the VMS+™4.0 advanced Automated Radiological Image Processing Software/System to the previous basic model, VMS+ 3.0. This latest advancement of Ventripoint’s proprietary technology, VMS+ 4.0, which recently received U.S. FDA 510(k) clearance, delivers a... Read more


GE HealthCare launches AI-driven, patient-friendly Invenia ABUS Premium to accelerate scanning and drive early cancer detection in dense breasts

The latest Invenia ABUS is designed to deliver optimal outcomes with its innovative, patient-friendly, and efficient AI-driven technology Invenia ABUS Premium features new integrated Verisound AI and AI Assistant, which ensure faster and reproducible scanning and reading with extraordinary image quality The non-invasive ultrasound technology, equipped with a novel Reverse Curve transducer and separate acquisition and reading capabilities, is built to enhance patient... Read more


ICON Becomes the First Large Clinical Research Organization to Fully Integrate Medidata Clinical Data Studio, Streamlining Data Management and Review

Adoption allows ICON to take full advantage of the Medidata “Data Experience,” leveraging AI to unify data sources, standardize outputs, and reduce reconciliation efforts NEW YORK / Mar 20, 2025 / Business Wire / Medidata, a Dassault Systèmes brand and leading provider of clinical trial solutions to the life sciences industry, today announced that ICON plc, (NASDAQ: ICLR) a world-leading clinical research organization (CRO) powered by healthcare intelligence, will... Read more


Quest Diagnostics to Collaborate with Google Cloud to Streamline Data and Personalize Customer Experiences Using Generative AI

SUNNYVALE, Calif. and SECAUCUS, N.J., March 18, 2025 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), a leader in diagnostic information services, today announced a collaboration with Google Cloud to streamline Quest's data management, improve data analytics, and personalize the experiences Quest delivers to patients, providers and other customers. To do so, Quest Diagnostics will use Google Cloud's data analytics and generative AI (gen AI) technologies, including Google... Read more


Hyperfine and NVIDIA Collaborate to Revolutionize Neuroimaging with AI-Powered Innovation

Collaboration aims to make portable MRI faster, smarter, and more accessible worldwide. GUILFORD, Conn. / Mar 17, 2025 / Business Wire / Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared AI-powered portable magnetic resonance (MR) brain imaging system—the Swoop® system—today announced a strategic collaboration with NVIDIA. This collaboration leverages NVIDIA AI expertise and... Read more


Partex and Fortress Biotech Announce Strategic Collaboration to Accelerate Asset Identification and Evaluation Using Proprietary AI Platform

FRANKFURT, Germany and MIAMI, March 17, 2025 (GLOBE NEWSWIRE) -- Partex NV and Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”), an innovative biopharmaceutical company, today announced a strategic collaboration aimed at identifying and evaluating biopharmaceutical compounds using artificial intelligence (AI) for potential acquisition or licensing by Fortress. Partex will deploy its proprietary AI-based drug discovery and development technology platform, which delivers... Read more


Perimeter Medical Imaging AI Files FDA PMA Application for its Next-Generation B-Series OCT with ImgAssist AI 2.0

TORONTO and DALLAS, March 17, 2025 /CNW/ - Perimeter Medical Imaging AI, Inc. (TSXV: PINK) (OTCQX: PYNKF) ("Perimeter" or the "Company"), a commercial-stage medical technology company, today announced the submission of a Premarket Approval ("PMA") application to the U.S. Food and Drug Administration ("FDA") for the Company's next-generation Perimeter B-Series OCT system, which combines proprietary artificial intelligence ("AI") technology with optical coherence... Read more


Spectral AI Announces Successful Results from its Burn Validation Study of the DeepView System

DeepView® System outperforms burn physicians in identifying non-healing tissue Landmark Burn Validation Study, one of the largest in U.S. history, confirms DeepView’s performance Spectral AI plans FDA submission by mid-2025, targeting De Novo Clearance and rapid commercialization to transform burn care DALLAS, March 17, 2025 (GLOBE NEWSWIRE) -- Spectral AI (NASDAQ: MDAI) (“Spectral AI” or the “Company”), developer of the AI-driven DeepView® System, that... Read more


GeneDx Enhances the Power of its Interpretation Platform with Artificial Intelligence (AI) Powered Gene Ranker to Enable Faster and More Efficient Clinical Analysis

GeneDx's Multiscore tool to be showcased at the American College of Medical Genetics and Genomics (ACMG) Annual Meeting GAITHERSBURG, Md. / Mar 13, 2025 / Business Wire / GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced Multiscore, an advanced AI-powered decision support tool designed to revolutionize genetic analysis by improving diagnostic efficiency, streamlining workflows, and enhancing clinical insights.... Read more


MeiraGTx Enters into a Strategic Collaboration with Hologen AI to Expedite Phase 3 Development of AAV-GAD for Parkinson’s Disease and Industrialize MeiraGTx’s Proprietary Manufacturing Process

MeiraGTx to receive $200 million in upfront cash consideration MeiraGTx and Hologen will form a joint venture, Hologen Neuro AI Ltd, with an additional $230 million committed capital from Hologen to fund 100% of the development of AAV-GAD for Parkinson’s disease through to commercialization, as well as other potential pipeline products MeiraGTx will enter into clinical and commercial supply agreements with Hologen Neuro AI Ltd to manufacture AAV-GAD and other locally... Read more


Next-Gen Cancer Treatment: Rakovina Therapeutics’ AI-Driven ATR Inhibitors Enter Preclinical Testing

VANCOUVER, British Columbia, March 12, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV)(FSE: 7JO), a biopharmaceutical company advancing innovative cancer therapies through artificial intelligence (AI)-powered drug discovery, announced today that the company has received the first synthesized batch of AI-generated ATR inhibitor compounds developed in collaboration with Variational AI. This milestone marks a significant step forward in Rakovina’s mission... Read more


Tempus Announces Acquisition of Deep 6 AI

Deep 6 is integrated with over 750 provider site locations spanning more than 30 million patients, which will materially add to Tempus’ existing network CHICAGO / Mar 11, 2025 / Business Wire / Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced it has acquired Deep 6 AI, a leading AI-powered precision research platform for healthcare organizations and life sciences companies. Deep... Read more


Ainos and ASE Partner to Power AI Scent Digitization in Semiconductor Manufacturing

Harnessing AI-Powered Scent Digitization for Smarter, Safer, and More Sustainable Factories With this collaboration, Ainos takes a major step in its mission to digitize scent - expanding its expertise from healthcare applications to industrial automation. AI Nose, originally developed for volatile organic compound (VOC) detection in medical diagnostics, is now expanding to smart factories. By unlocking insights from invisible chemical patterns in the air, AI Nose has... Read more


COEPTIS’ NexGenAI Affiliates Partners with NUBURU Network to Drive Innovation in AI and Robotics as Part of its Transformation Plan

WEXFORD, Pa., March 07, 2025 (GLOBE NEWSWIRE) -- COEPTIS, Inc. (Nasdaq: COEP) ("the Company" or "COEPTIS"), a pioneering technology firm at the forefront of innovative biotechnology solutions today announced its strategic partnership with COEPTIS’ NexGenAI Affiliates Network “NexGen” and NUBURU, Inc. “NUBURU” (NYSE: BURU), a leading innovator in high-power blue laser technology. This collaboration is a pivotal component of COEPTIS’ strategic position in technology... Read more


Hemostemix and FireFly Neuroscience's Brain Network Analytics (BNA(TM)) Engage to Complete Phase 1 Vascular Dementia Clinical Trial of ACP-01

A growing body of clinical evidence supports the use of Firefly's FDA-Cleared BNA(TM) platform to study ACP-01 as a treatment for vascular dementia Calgary, Alberta--(Newsfile Corp. - March 6, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or "HEM"), an autologous angiogenic stem cell company that has safely treated 498 patients for various forms of cardiovascular disease, including vascular dementia, announces its collaboration with... Read more


PainReform Completes Strategic Acquisition of DeepSolar, Unlocking New Growth Opportunities in AI-Driven Solar Analytics

TEL AVIV, Israel, March 05, 2025 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) ("PainReform" or the "Company"), a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today announced the successful closing of its previously announced acquisition of 100% of the business activity of DeepSolar, an AI-driven solar analytics platform, from BladeRanger Ltd, a public company registered under the laws of the State of Israel,... Read more


Lisata Therapeutics and GATC Health Consummate First Step in Strategic Collaboration to use AI to Derisk and Accelerate Drug Development

Strategic collaboration harnesses GATC’s proprietary Artificial Intelligence-powered, validated Multiomics Advanced Technology™ platform to rapidly optimize and derisk drug discovery and development, thereby accelerating and economizing the traditional drug development process. Lisata’s investigational product, certepetide, to be the subject of a comprehensive AI-analysis to determine optimum disease targets and development strategies. GATC to leverage Lisata’s... Read more


IGC Pharma Expands AI Platform With Advanced Diagnostic Model for Alzheimer's and Dementia Detection

POTOMAC, MD / ACCESS Newswire / March 4, 2025 / IGC Pharma, Inc. ("IGC" or the "Company") (NYSE American:IGC) today announced an advancement in its Artificial Intelligence ("AI") platform with the development of a new AI-driven model designed to improve the diagnosis of Alzheimer's disease (AD) and other causes of dementia. With Alzheimer's accounting for approximately 60-80% of all dementia cases, alongside other conditions such as vascular disease, Lewy body disease,... Read more


Clover Health: Counterpart Health Partners with Google Cloud to Improve Clinical Data Access for Physicians

WILMINGTON, Del., March 03, 2025 (GLOBE NEWSWIRE) -- Counterpart Health, Inc. (“Counterpart”), a leading AI-powered physician enablement platform, today announced it has partnered with Google Cloud to integrate Vertex AI Search into its flagship technology, Counterpart Assistant. This innovation gives providers on Counterpart Assistant a generative AI (gen AI) search experience across the breadth of a patient’s digital health record to provide contextualized insights,... Read more


IDEAYA Biosciences Announces Collaboration with ATTMOS to Accelerate AI/ML-Enabled Drug Discovery for Unprecedented First-in-Class Oncology Targets

SOUTH SAN FRANCISCO, Calif., March 3, 2025 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, today announced a research collaboration with ATTMOS as part of its efforts to build a physics-based computational small molecule discovery platform that rapidly unlocks what are currently perceived as undruggable oncology targets. The collaboration will integrate IDEAYA's... Read more



Rakovina Therapeutics and Variational AI Strengthen Partnership

VANCOUVER, British Columbia, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV) (FSE: 7JO), a biopharmaceutical company advancing cancer therapies based on DNA-damage response technologies, proudly reaffirms its strategic partnership with Variational AI. This announcement comes on the heels of Variational AI’s impressive $5.5 million oversubscribed financing round, led by Nimbus Synergies with participation from Flying Fish Ventures, Merck Global... Read more


ImmunoPrecise Antibodies and RIBOPRO Partner to Advance mRNA-Driven Antibody Discovery, Unlocking New Frontiers in Immunotherapy

AUSTIN, Texas / Feb 26, 2025 / Business Wire / ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) (“IPA” or the “Company”), a global leader in AI-powered antibody discovery and development, today announced a strategic collaboration with RIBOPRO, a pioneering technology provider specializing in mRNA and lipid nanoparticle (LNP) technologies. This collaboration seeks to revolutionize the discovery and development of therapeutic antibodies by integrating RIBOPRO’s advanced... Read more


HEALWELL AI's VeroSource Unveils Digital Twin Technology to Bring Real-Time Intelligence to Healthcare Management

VeroSource to support cutting edge Digital Twin technology on its VS Data-as-a-Service Platform, delivering real-time insights and advanced data visualization to optimize healthcare operations. A Digital Twin is a virtual model of a healthcare system or facility that provides real-time insights for better decision-making. By simulating operations without disruption, this technology allows healthcare managers to optimize efficiency, reduce costs, and enhance patient care. Key... Read more


RadNet: DeepHealth Introduces New AI-Powered Radiology Informatics and Population Screening Solutions at #ECR2025

At ECR 2025, DeepHealth will introduce new AI-powered radiology informatics and cancer screening solutions enabled by DeepHealth OS, its pioneering cloud-native operating system, to address clinical and operational challenges. DeepHealth aims to bring to European customers its Diagnostic Suite™ to redefine the traditional Picture Archiving and Communication System (PACS) with a unified workspace tailored for modern radiology, and SmartMammo™, an AI-powered end-to-end... Read more


Netramark And The Ontario Brain Institute Partner To Advance AI-Powered Neuroanalytics For Major Depression Research

TORONTO, Feb. 25, 2025 /CNW/ - NetraMark Holdings Inc. (the "Company" or "NetraMark") (CSE: AIAI) (OTCQB: AINMF) (Frankfurt: 8TV) a generative AI software leader in clinical trial analytics, announces its funded collaboration with the Ontario Brain Institute (OBI) to enhance the analysis of brain imaging and multi-modal data from Major Depressive Disorder (MDD) clinical research to achieve treatment separation in future clinical trials. The collaboration,... Read more


RadNet’s Wholly-Owned Subsidiary, DeepHealth, and ConcertAI’s TeraRecon Announce Strategic Collaboration Around Integrated AI and Advanced Visualization

DeepHealth’s cloud-native Diagnostic Suite™ will integrate TeraRecon’s SaaS-based advanced visualization capabilities, creating a unified AI-powered diagnostic workspace that enhances workflows and expands access to advanced diagnostic tools across diverse healthcare settings. The collaboration will also integrate DeepHealth’s clinical AI solutions into TeraRecon’s AI ecosystem, augmenting its capabilities and expanding its impact in diagnostic imaging. Both... Read more


Myriad Genetics Partners with PATHOMIQ to add Artificial Intelligence Technology Platform to its Oncology Portfolio

SALT LAKE CITY, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, and PATHOMIQ, Inc., a developer of artificial intelligence (AI)-enabled prognostic and predictive tests for advancing access to personalized medicine and empowering treatment decisions, announced that they have entered into a strategic collaboration for Myriad to exclusively license PATHOMIQ_PRAD, PATHOMIQ’s AI technology... Read more



HEALWELL AI's Khure Health Provides Update Highlighting Significant Acceleration in User and Life Sciences Partner Adoption of Disease Detection AI Powered Co-Pilots and Strong Physician NPS Scores

In Q4-2024, HEALWELL's subsidiary, Khure Health ("Khure") helped physicians identify over 43,000 high-risk patients with its AI-Powered Physician Co-Pilots, across 8 clinical specialities harnessing 132 disease specific algorithms. This figure reflected a quarter over quarter sequential growth of 22% as compared to Q3-2024 and year-over-year growth of 500% as compared to Q4-2023. HEALWELL has executed 4 new Master Services Agreements ("MSA") with new pharmaceutical partners... Read more


COEPTIS’ NexGenAI Partners with Arketyp Valu to Revolutionize Digital Engagement on the Verus Network

WEXFORD, Pa., Feb. 20, 2025 (GLOBE NEWSWIRE) -- COEPTIS, Inc. (Nasdaq: COEP) ("the Company" or "Coeptis"), a pioneering technology firm at the forefront of innovative biotechnology solutions today announced an exciting strategic partnership with COEPTIS’ NexGenAI Affiliates Network and Arketyp Valu, a prominent developer within the open-source Verus Project, which has recently achieved a market capitalization exceeding $500 million. This collaboration aims to integrate... Read more


Incyte and Genesis Therapeutics Announce Strategic AI-focused Research Collaboration

Incyte and Genesis will leverage Genesis’ GEMS artificial intelligence (AI) platform to unlock the discovery of breakthrough small molecule therapeutics against Incyte-selected targets Incyte receives exclusive rights to develop and commercialize collaboration products WILMINGTON, Del. & BURLINGAME, Calif. / Feb 20, 2025 / Business Wire / Incyte (Nasdaq:INCY) and Genesis Therapeutics, Inc. announced today that the companies have entered into a strategic collaboration... Read more


Conduit Pharmaceuticals Progresses Phase II of its AI Initiative with Sarborg

Collaboration reinforces Conduit’s commitment to leveraging AI and cybernetics to reduce human error, lower costs, and accelerate timelines in drug development Sarborg delivers a prototype AI-product to Conduit’s Management team NAPLES, Fla. and CAMBRIDGE, United Kingdom, Feb. 20, 2025 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Inc. (Nasdaq: CDT) (“Conduit” or the “Company”), is pleased to announce the completion of the initial milestones in Phase II... Read more



PainReform Executes Definitive Agreement to Acquire DeepSolar, Marking a Unique Expansion Opportunity

DeepSolar brings new customer base in creation, including major utility-scale solar operators and independent power producers, while breaking into the residential solar market The Company remains committed to advancing its drug delivery technologies while broadening its growth potential TEL AVIV, Israel, Feb. 18, 2025 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) ("PainReform" or the "Company"), a clinical-stage specialty pharmaceutical company focused on the... Read more


Predictive Oncology Reports Positive Results Utilizing Artificial Intelligence for Drug Repurposing

Company successfully identified several abandoned or discontinued drugs for further testing and development in ovarian and other cancer types Creates significant business development opportunities with meaningful long-term commercial potential with large pharmaceutical companies PITTSBURGH, Feb. 18, 2025 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI), a leader in AI-driven drug discovery and biologics, today provided an update highlighting new successes... Read more


Kovo+ Announces Letter of Intent to Acquire Exclusive Rights to AI Vector and Veebas

Vancouver, British Columbia--(Newsfile Corp. - February 13, 2025) - Kovo+ Holdings Inc. (formerly Kovo HealthTech Corporation) (TSXV: KOVO) ("Kovo" or the "Company") is pleased to announce that it has entered into a non-binding letter of intent (the "LOI") with Avonlea Ventures #2 Inc. ("AVI"), whereby the Company intends to acquire (the "Proposed Transaction") certain contractual assets of AVI, including the exclusive right to acquire, among other things: (i) all of the... Read more


CareSpan Health Enters Into Definitive Agreement With Medtech AI And Concurrent Financing

VANCOUVER, BC, Feb. 13, 2025 /CNW/ - CareSpan Health, Inc. (TSXV: CSPN) (the "Company" or "CareSpan"), announces that it has entered into a binding definitive agreement among Medtech AI Inc. ("Medtech"), a company incorporated under the laws of Ontario, and 1001132953 Ontario Inc., a company existing under the laws of Ontario, (the "SubCo") effective as of February 11, 2025 (the "Definitive Agreement"), whereby CareSpan will acquire all the issued and outstanding common... Read more


HEALWELL AI's Pentavere Publishes Study in the Journal of Liquid Biopsy; Validating DARWEN(TM) AI as a Leading Artificial Intelligence Clinical Decision Support Tool in Oncology

The use of the DARWEN™ AI platform achieved time savings representing a 100-fold improvement as compared to traditional manual processes(1), demonstrating the opportunity to advance care and improve patient outcomes by leveraging cutting edge AI technology in clinical care. This study was conducted in collaboration with Princess Margaret Cancer Centre and is one of the world's first peer-reviewed studies to use an artificial intelligence platform to demonstrate... Read more


Cosmos Health Advances Cancer Treatment Innovation with Two New AI-Driven Patent Filings for Gliomas and Hematologic Malignancies; $25 Billion+ Global Market

CHICAGO, IL / ACCESS Newswire / February 10, 2025 / Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQ:COSM), a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor of healthcare products, and operator of a telehealth platform, announced today the filing of two new patent applications, covering groundbreaking developments in the treatment... Read more


Conduit Pharmaceuticals Transitions to Phase II of Sarborg Collaboration to Support AI-Driven Drug Development

Conduit and Sarborg complete all milestones of Phase I of their AI-driven drug development collaboration, and commence transitioning to Phase II, which will focus on developing personalized software dashboards to enhance efficiency, decision-making, and operational agility of its current and future portfolio NAPLES, Fla. and CAMBRIDGE, United Kingdom, Feb. 07, 2025 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Inc. (Nasdaq: CDT) (“Conduit” or the “Company”),... Read more